A novel peptide probe for imaging and targeted delivery of liposomal @entity632 to XXXX .

@entity1 @entity632 @entity5 @entity19 @entity2
Targeted delivery of imaging agents and therapeutics to @entity5 would provide early detection and increased therapeutic efficacy against @entity5 . Here we have screened a phage-displayed peptide library to identify peptides that selectively bind to @entity2 cells. Evaluation of individual phage clones after screening revealed that a phage clone displaying the CSNIDARAC peptide bound to @entity1 @entity2 cells at higher extent than other phage clones. The synthetic CSNIDARAC peptide strongly bound to @entity1 cells and was efficiently internalized into the cells, while little binding of a control peptide was seen. It also preferentially bound to other @entity2 cell lines as compared to cells of different @entity5 types. In vivo imaging of @entity2 was achieved by homing of fluorescence dye-labeled CSNIDARAC peptide to the @entity5 after intravenous injection into @entity19 . Ex vivo imaging and microscopic analysis of isolated organs further demonstrated the targeting of CSNIDARAC peptide to @entity5 . The CSNIDARAC peptide-targeted and @entity632 -loaded liposomes inhibited the @entity5 growth more efficiently than untargeted liposomes or free @entity632 . In vivo imaging of fluorescence dye-labeled liposomes demonstrated selective homing of the CSNIDARAC-liposomes to @entity5 . In the same context, higher levels of @entity632 and apoptosis in @entity5 tissue were observed when treated with the targeted liposomes than untargeted liposomes or free @entity632 . These results suggest that the CSNIDARAC peptide is a promising targeting probe that is able to direct imaging agents and therapeutics to @entity2 .
